Indapta Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.indapta.com
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis
Phase 1
Not yet recruiting
- Conditions
- Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)Non-Active Secondary Progressive Multiple SclerosisNon-Active SPMSAutoimmune Diseases of the Nervous SystemNervous System DiseasesAutoimmune DiseasesDemyelinating DiseasesImmune System Diseases
- Interventions
- First Posted Date
- 2024-11-07
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 34
- Registration Number
- NCT06677710
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸AdventHealth Orlando - Adventist Health System/Sunbelt, Inc., Orlando, Florida, United States
🇺🇸Stanford University, Stanford, California, United States
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Indapta Therapeutics, INC.
- Target Recruit Count
- 128
- Registration Number
- NCT06119685
- Locations
- 🇺🇸
Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Stanford University, Stanford, California, United States
🇺🇸Florida Cancer Specialists and Research Institute - Lake Mary Cancer Center, Lake Mary, Florida, United States
© Copyright 2024. All Rights Reserved by MedPath